

# John S Schieffelin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/786002/publications.pdf>

Version: 2024-02-01

63  
papers

1,880  
citations

361413

20  
h-index

276875

41  
g-index

66  
all docs

66  
docs citations

66  
times ranked

2986  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	5
2	Evaluation of Three Clinical Prediction Tools to Predict Mortality in Hospitalized Patients with Lassa Fever. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 107, 856-862.	1.4	3
3	Clinical features and viral RNA shedding of imported and local cases with COVID-19 in Wenzhou, China. <i>Medicine (United States)</i> , 2021, 100, e24826.	1.0	1
4	Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012â€“2019. <i>Microorganisms</i> , 2021, 9, 586.	3.6	10
5	Boosting understanding of Lassa Fever virus epidemiology: Field testing a novel assay to identify past Lassa Fever virus infection in blood and oral fluids of survivors and unexposed controls in Sierra Leone. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009255.	3.0	0
6	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. <i>Immunity</i> , 2021, 54, 815-828.e5.	14.3	34
7	Newâ€“onset atrial arrhythmias associated with mortality in black and white patients hospitalized with COVIDâ€“19. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 856-864.	1.2	8
8	What should define a SARS-CoV-2 â€œbreakthroughâ€“infection?. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	18
9	Implementation of the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) study: Lessons learned for vision health systems strengthening in Sierra Leone. <i>PLoS ONE</i> , 2021, 16, e0252905.	2.5	5
10	Health seeking behavior after the 2013â€“16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009576.	3.0	8
11	The Origins and Future of Sentinel: An Early-Warning System for Pandemic Preemption and Response. <i>Viruses</i> , 2021, 13, 1605.	3.3	8
12	Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. <i>Viruses</i> , 2021, 13, 2325.	3.3	24
13	SARS-CoV-2 seroprevalence rates of children seeking medical care in Louisiana during the state stay at home order. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100047.	1.0	3
14	Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. <i>Scientific Reports</i> , 2020, 10, 16030.	3.3	15
15	Elevated l-threonine is a biomarker for Lassa fever and Ebola. <i>Virology Journal</i> , 2020, 17, 188.	3.4	7
16	Lassa Fever Induced Hearing Loss: The Neglected Disability of Hemorrhagic Fever. <i>International Journal of Infectious Diseases</i> , 2020, 100, 82-87.	3.3	14
17	Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses. <i>Journal of Infectious Diseases</i> , 2020, 221, 156-161.	4.0	35
18	Responses of three urban U.S. Childrenâ€™s Hospitals to COVID-19: Seattle, New York and New Orleans. <i>Paediatric Respiratory Reviews</i> , 2020, 35, 15-19.	1.8	7

#	ARTICLE	IF	CITATIONS
19	High crossreactivity of human T cell responses between Lassa virus lineages. PLoS Pathogens, 2020, 16, e1008352.	4.7	22
20	Infectious Disease Outbreaks: The Need For an All-in Approach. Journal of Infectious Diseases, 2020, 222, 1941-1942.	4.0	0
21	Identification of Common CD8 <sup>+</sup> T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone. Journal of Virology, 2020, 94, .	3.4	15
22	Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. Scientific Reports, 2020, 10, 8724.	3.3	14
23	Ebola-Specific CD8 <sup>+</sup> and CD4 <sup>+</sup> T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae. Journal of Infectious Diseases, 2020, 222, 1488-1497.	4.0	13
24	Ophthalmic manifestations and vision impairment in Lassa fever survivors. PLoS ONE, 2020, 15, e0243766.	2.5	17
25	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
26	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
27	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
28	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
29	Expanding Research Capacity in Sub-Saharan Africa Through Informatics, Bioinformatics, and Data Science Training Programs in Mali. Frontiers in Genetics, 2019, 10, 331.	2.3	26
30	Data set on Lassa fever in post-conflict Sierra Leone. Data in Brief, 2019, 23, 103673.	1.0	12
31	A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. PLoS ONE, 2019, 14, e0214284.	2.5	14
32	Dengue and chikungunya seroprevalence among Qatari nationals and immigrants residing in Qatar. PLoS ONE, 2019, 14, e0211574.	2.5	19
33	Congenital Cytomegalovirus Infection. Ochsner Journal, 2019, 19, 123-130.	1.1	32
34	A Review of Hearing Loss Associated with Zika, Ebola, and Lassa Fever. American Journal of Tropical Medicine and Hygiene, 2019, 101, 484-490.	1.4	24
35	Emerging Trends in Clinical Tropical Medicine Research. American Journal of Tropical Medicine and Hygiene, 2019, 101, 8-11.	1.4	0
36	Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Scientific Reports, 2018, 8, 5939.	3.3	39

#	ARTICLE	IF	CITATIONS
37	Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone. <i>EBioMedicine</i> , 2018, 30, 217-224.	6.1	42
38	Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in Adults With Suspected Infection in Low- and Middle-Income Countries. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2202.	7.4	147
39	Analysis of CD8 <sup>+</sup> T cell response during the 2013–2016 Ebola epidemic in West Africa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7578-E7586.	7.1	55
40	Derivation and validation of a universal vital assessment (UVA) score: a tool for predicting mortality in adult hospitalised patients in sub-Saharan Africa. <i>BMJ Global Health</i> , 2017, 2, e000344.	4.7	58
41	An effective and safe vaccine will not be enough to prepare us for the next Ebola outbreak. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1224-1225.	9.1	4
42	Hansen’s Disease and Rheumatoid Arthritis Crossover of Clinical Symptoms: A Case Series of 18 Patients in the United States. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1726-1730.	1.4	9
43	An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. <i>Journal of Infectious Diseases</i> , 2016, 214, S110-S121.	4.0	34
44	Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. <i>Nature Communications</i> , 2016, 7, 11544.	12.8	148
45	Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, S210-S217.	4.0	35
46	Ebola virus disease and critical illness. <i>Critical Care</i> , 2016, 20, 217.	5.8	97
47	Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, S203-S209.	4.0	29
48	Clinical validation trial of a diagnostic for Ebola Zaire antigen detection: Design rationale and challenges to implementation. <i>Clinical Trials</i> , 2016, 13, 66-72.	1.6	12
49	A Unified Framework for the Infection Dynamics of Zoonotic Spillover and Spread. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004957.	3.0	52
50	Development of Prototype Filovirus Recombinant Antigen Immunoassays. <i>Journal of Infectious Diseases</i> , 2015, 212, S359-S367.	4.0	30
51	Multiple Circulating Infections Can Mimic the Early Stages of Viral Hemorrhagic Fevers and Possible Human Exposure to Filoviruses in Sierra Leone Prior to the 2014 Outbreak. <i>Viral Immunology</i> , 2015, 28, 19-31.	1.3	33
52	Factors Associated with Mortality in Febrile Patients in a Government Referral Hospital in the Kenema District of Sierra Leone. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 172-177.	1.4	11
53	Using Modelling to Disentangle the Relative Contributions of Zoonotic and Anthroponotic Transmission: The Case of Lassa Fever. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e3398.	3.0	96
54	Treatment of Arenavirus Infections. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 261-270.	1.9	4

#	ARTICLE	IF	CITATIONS
55	Raising the standard for clinical care of patients with Ebola virus disease. <i>Lancet Infectious Diseases</i> , 2015, 15, 1247-1248.	9.1	6
56	Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. <i>Cell</i> , 2015, 162, 738-750.	28.9	230
57	Lassa Fever in Post-Conflict Sierra Leone. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2748.	3.0	172
58	A tribute to Sheik Humarr Khan and all the healthcare workers in West Africa who have sacrificed in the fight against Ebola virus disease: Mae we hush. <i>Antiviral Research</i> , 2014, 111, 33-35.	4.1	19
59	Dengue fever: a new challenge for China?. <i>Global Health Action</i> , 2014, 7, 26421.	1.9	9
60	Does Screening Keep Ebola Out of USA?. <i>Tropical Medicine &amp; Surgery</i> , 2014, 02, .	0.1	0
61	How natural disasters change natural patterns: coccidioidomycosis imported to New Orleans. <i>The Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society</i> , 2013, 165, 145-9.	0.1	3
62	Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. <i>Virology Journal</i> , 2010, 7, 28.	3.4	87
63	Zika Virus Replication in a Mast Cell Model is Augmented by Dengue Virus Antibody-Dependent Enhancement and Features a Selective Immune Mediator Secretory Profile. <i>Microbiology Spectrum</i> , 0, , .	3.0	1